NeuroBo Pharmaceuticals, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
8NeuroBo Pharmaceuticals's Business Model
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
About NeuroBo Pharmaceuticals
Website: https://www.neurobopharma.com
CEO (Chief Executive Officer): Mr. Hyung-Heon Kim
IPO date: 2016-08-05
Contact
Country: US
Address: 200 Berkeley Street
City: Boston
State: MA
Phone: 857 702 9600
Zip Code: 02116
Other
CIK: 0001638287
ISIN: US64132R4048
CUSIP: 64132R107
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
